Pharmaceutics (Feb 2021)

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines

  • Basmah N. Aldosari,
  • Iman M. Alfagih,
  • Alanood S. Almurshedi

DOI
https://doi.org/10.3390/pharmaceutics13020206
Journal volume & issue
Vol. 13, no. 2
p. 206

Abstract

Read online

There has been increased interest in the development of RNA-based vaccines for protection against various infectious diseases and also for cancer immunotherapies. Rapid and cost-effective manufacturing methods in addition to potent immune responses observed in preclinical and clinical studies have made mRNA-based vaccines promising alternatives to conventional vaccine technologies. However, efficient delivery of these vaccines requires that the mRNA be protected against extracellular degradation. Lipid nanoparticles (LNPs) have been extensively studied as non-viral vectors for the delivery of mRNA to target cells because of their relatively easy and scalable manufacturing processes. This review highlights key advances in the development of LNPs and reviews the application of mRNA-based vaccines formulated in LNPs for use against infectious diseases and cancer.

Keywords